Real World Data of patient experience and side effects presented at the 2025 World Conference on Lung Cancer
At the 2025 World Conference on Lung Cancer (WCLC), new evidence was presented from the CLIMEDIN study, a prospective clinical trial exploring how patients with advanced non-small cell lung cancer (NSCLC) engage digitally to report their symptoms and receive personalised support.
The study leverages the CareAcross online platform to collect patient-reported outcomes in real time. Its goal: to evaluate the feasibility and impact of digital symptom monitoring on patients’ quality of life, healthcare resource use, and clinical outcomes.
Capturing the patient voice, digitally
Following their diagnosis and treatment initiation, 200 patients were invited to report on 22 pre-defined adverse events (AEs) through the online platform. 188 patients submitted symptom reports an average of 37 times during the study, illustrating that even patients facing advanced disease can and do engage consistently in digital health initiatives.
As reported in other conferences, patients in the intervention arm experienced more improvements in adverse events, and were also associated with lower hospitalisation costs:
ASCO 2025 oral presentation
ASCO 2024 oral presentation
ESMO 2023 poster
What patients reported
The most frequently symptoms at least once were fatigue (88%), cough (63%), anorexia (54%), and nausea (51%), followed by gastrointestinal and respiratory-related side effects. Interestingly, subgroup analyses by age, education, and location revealed only minor differences in symptom patterns, highlighting the broad applicability of digital engagement across diverse patient populations.
From real-world data to better care
The CLIMEDIN results demonstrate the feasibility of continuous online symptom reporting and the value of real-world data in oncology. Patient-reported outcomes (PROs) collected digitally can enhance understanding of the lived experience of cancer, inform patient-centered care, and potentially support earlier intervention for emerging side effects.
By facilitating the timely flow of information between patients and their clinical teams, digital platforms can play a meaningful role in improving quality of life and care effectiveness for people living with cancer.
Acknowledgements
CareAcross is grateful for the patients participating in this study. We would also like to acknowledge HeCOG as the leading partner in this study, recognise the important help of healthcare professionals, as well as the funding this study received from the Stavros Niarchos Foundation.
This work underscores the importance of integrating patient perspectives into everyday oncology practice. Learn more about how digital engagement and real-world evidence can empower cancer care at CareAcross.com.